Barriers and facilitators for family physicians prescribing opioid agonist therapy in Saskatchewan

被引:0
|
作者
Nguyen, Teresa [1 ]
Bareham, Julia [2 ]
Halpape, Katelyn [3 ]
机构
[1] Loblaw Pharm Saskatoon, Saskatoon, SK, Canada
[2] Univ Saskatchewan, RxFiles Acad Detailing Program, Saskatoon, SK, Canada
[3] Univ Saskatchewan, Coll Pharm & Nutr, Saskatoon, SK, Canada
关键词
COLLABORATIVE CARE; BUPRENORPHINE; EXPERIENCE; ABSTINENCE; ADDICTION; METHADONE;
D O I
10.46747/cfp.7004e52
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Objective To explore barriers and facilitators for family physicians in Saskatchewan prescribing opioid agonist therapy (OAT). Design Self-administered postal survey. Setting Family medicine practices in Saskatchewan. Participants A total of 218 Saskatchewan family physicians who were not authorized to prescribe OAT as of June 2022. Main outcome measures Descriptive and inferential statistics of physicians' self-reported barriers to and facilitators of prescribing OAT for opioid use disorder (OUD). Results Most respondents (84.8%) had some comfort with diagnosing OUD. However, more than half (58.3%) did not feel confident or knowledgeable about prescribing OAT. Barriers to OAT prescribing included lack of time, incomplete training requirements, lack of interest, insufficient funding or support, feeling overwhelmed, and perceiving that OAT does not work and thus is not necessary. Physicians working in core neighbourhoods and those receiving fee-for-service compensation reported the least available time to prescribe OAT. Conversely, physicians working in interdisciplinary team settings had increased time for OAT prescribing compared with physicians in other settings. Having a close personal relationship with someone with OUD was correlated with increased comfort in diagnosing OUD as well as with knowledge about and confidence in prescribing OAT. Themes identified as facilitators to increasing OAT prescribing included the addition of resources and supports, increased training, more awareness about OUD and OAT, enhanced compensation, and altered prescribing regulations. Conclusion Despite the presence of several real and perceived barriers limiting OAT prescribing by Saskatchewan family physicians, there are family physicians interested in providing this therapy. Increased clinical resources and support, including increased interdisciplinary practice, are actionable steps that should be considered by policy decision makers to address this issue. Additionally, increased OUD and OAT education, which includes the perspectives of those with lived experience of OUD, would help address physician confidence, knowledge, and awareness in this area.
引用
收藏
页码:e52 / e60
页数:9
相关论文
共 50 条
  • [21] Barriers Rural Physicians Face Prescribing Buprenorphine for Opioid Use Disorder
    Andrilla, C. Holly A.
    Coulthard, Cynthia
    Larson, Eric H.
    ANNALS OF FAMILY MEDICINE, 2017, 15 (04) : 359 - 362
  • [22] Barriers and facilitators to buprenorphine use for opioid agonist treatment: protocol for a scoping review
    Leece, Pamela
    Khorasheh, Triti
    Corace, Kimberly
    Strike, Carol
    Bayoumi, Ahmed M.
    Taha, Sheena
    Marks, Elisabeth
    Pach, Beata
    Ahamad, Keith
    Grennell, Erin
    Holowaty, Melissa
    Manson, Heather
    Straus, Sharon E.
    BMJ OPEN, 2019, 9 (12):
  • [23] Barriers and Facilitators to Using Statins: A Qualitative Study With Patients and Family Physicians
    Butalia, Sonia
    Lee-Krueger, Rachelle C. W.
    Mcbrien, Kerry A.
    Leung, Alexander A. C.
    Anderson, Todd J.
    Quan, Hude
    Naugler, Christopher
    Chen, Guanmin
    Campbell, David J. T.
    CJC OPEN, 2020, 2 (06) : 530 - 538
  • [24] Partner notification by family physicians for sexually transmitted infections Facilitators and barriers
    Choi, Alexandra
    Campbell, Audrey
    Consolacion, Theodora
    Pawa, Jasmine
    Ng, Brian
    Wong, Jason
    CANADIAN FAMILY PHYSICIAN, 2022, 68 (06) : E182 - E189
  • [25] Clustering of opioid prescribing and opioid-related mortality among family physicians in Ontario
    Dhalla, Irfan A.
    Mamdani, Muhammad M.
    Gomes, Tara
    Juurlink, David N.
    CANADIAN FAMILY PHYSICIAN, 2011, 57 (03) : E92 - E96
  • [26] Regional Variation in Benzodiazepme Prescribing for Patients on Opioid Agonist Therapy
    Park, Tae Woo
    Bohnert, Amy S.
    Austin, Karen L.
    Saitz, Richard
    Pizer, Steven D.
    PSYCHIATRIC SERVICES, 2014, 65 (01) : 4 - 4
  • [27] Scoping Review of Barriers and Facilitators of Breastfeeding in Women on Opioid Maintenance Therapy
    Doerzbacher, Margaret
    Sperlich, Mickey
    Hequembourg, Amy
    Chang, Yu-Ping
    JOGNN-JOURNAL OF OBSTETRIC GYNECOLOGIC AND NEONATAL NURSING, 2022, 51 (01): : 29 - 40
  • [28] Barriers and facilitators to medications for Opioid Use prescribing in primary care in the United States: a scoping review
    Ukaoma, Stella C.
    Kedia, Satish K.
    Regmi, Sanjaya
    Entwistle, Coree
    Lee, Guijin
    Dillon, Patrick J.
    DRUGS-EDUCATION PREVENTION AND POLICY, 2025,
  • [29] Barriers and facilitators to nurse practitioner buprenorphine prescribing for opioid use disorder in primary care settings
    Speight, Chandra
    Caiola, Courtney
    Tyndall, Deborah E.
    Scott, Elaine S.
    JOURNAL OF THE AMERICAN ASSOCIATION OF NURSE PRACTITIONERS, 2023, 35 (02) : 112 - 121
  • [30] Facilitators and Barriers to Interprofessional Teamwork within Family Medicine Practices: Physicians' Perspectives
    Bell, Neil
    Szafran, Olga
    Robertson, Sandra
    Williams, Beverly
    INTERNATIONAL JOURNAL OF QUALITATIVE METHODS, 2014, 13 : 481 - 481